The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification and external validation of clinical-molecular features to predict benefit from oxaliplatin reintroduction/rechallenge in patients with refractory metastatic colorectal cancer (mCRC).
 
Francesc Salva
Honoraria - Amgen; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen
 
Rafael Paes
Speakers' Bureau - MSD Oncology
 
Matheus Costa e Silva
Employment - Grupo Oncoclínicas; Rede D'Or São Luiz
 
Heloisa Cruz
No Relationships to Disclose
 
Nadia Saoudi Gonzalez
Speakers' Bureau - AMGEN
 
Iosune Baraibar
Travel, Accommodations, Expenses - Amgen; Merck; Sanofi
 
Javier Ros Montañá
Speakers' Bureau - Sanofi
 
Raquel Comas
No Relationships to Disclose
 
Fiorella Ruiz-Pace
No Relationships to Disclose
 
Ariadna Garcia
No Relationships to Disclose
 
Renata Dalpino
No Relationships to Disclose
 
Alexandre A. Jácome
Consulting or Advisory Role - Lilly; SERVIER
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; BMS Brazil; Roche; SERVIER; SERVIER
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bristol Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Genentech (Inst); HalioDx (Inst); Hutchison MediPharma (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Stock and Other Ownership Interests - Trialing Health
Consulting or Advisory Role - Boehringer Ingelheim; Foundation Medicine; Roche
Speakers' Bureau - Amgen; AstraZeneca; GlaxoSmithKline; Ipsen; Libbs; Lilly; MSD Oncology; Roche; Sanofi; SERVIER
Research Funding - Merck